The Forum-Shopping Endgame: Eighth Circuit Hands Bayer a State-Court Fortress for Its $7.25 Billion Roundup Settlement
The Eighth Circuit's dismissal last week of objectors' appeal in the Roundup litigation marks more than a procedural footnote—it confirms that Bayer has successfully engineered a jurisdictional moat around its $7.25 billion class settlement, effectiv...
The Eighth Circuit's dismissal last week of objectors' appeal in the Roundup litigation marks more than a procedural footnote—it confirms that Bayer has successfully engineered a jurisdictional moat around its $7.25 billion class settlement, effectively insulating the deal from federal appellate scrutiny and shifting the center of gravity in mass tort resolution away from federal MDLs and toward state-court class mechanisms.
By dismissing the appeal on August 27, the Eighth Circuit ratified a fundamental strategic reality: defendants facing sprawling mass tort exposure can now use removal jurisdiction not as a shield to get into federal court, but as a sword to keep objectors out. The court held that because the settlement was structured as a state-court class action in Missouri—Bayer's home turf, where the company has cultivated relationships and where state procedural rules may be more forgiving than the federal Rule 23(e) fairness gauntlet—federal appellate review was unavailable.
The Jurisdictional Trap Door
The decision rests on a straightforward application of removal jurisdiction principles, but its implications are anything but routine. When Bayer reached its settlement with state-court plaintiffs' counsel, it deliberately bypassed the federal multidistrict litigation (MDL) pending before Judge Vince Chhabria in the Northern District of California. Objectors—primarily plaintiffs who had filed federal cases and opposed the settlement's release provisions—attempted to remove the state-court class action to federal court, presumably hoping to access federal appellate review under Rule 23(f) or to challenge the settlement's adequacy under the stricter scrutiny that federal courts have applied post-Amchem Products, Inc. v. Windsor, 521 U.S. 591 (1997).
The Eighth Circuit said no. By affirming the district court's refusal to exercise jurisdiction, the appellate panel has effectively created a settlement safe harbor: if a defendant can convince a critical mass of plaintiffs' counsel to file in state court and structure a class settlement there, federal courts lack the power to supervise the deal's fairness, adequacy of representation, or the scope of releases—even when the settlement purports to resolve claims that overlap with pending federal litigation.
This is forum selection as settlement architecture. Bayer isn't just choosing a friendly venue; it's choosing a venue with no appellate oversight.
The Post-SCOTUS Landscape
This maneuver gains particular significance in light of the Supreme Court's 2026 ruling in Bayer's favor on preemption grounds—a decision that has already begun reshaping the Roundup litigation's terrain. While the specific holding of that case addressed the viability of failure-to-warn claims under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), its broader effect has been to embolden Bayer's strategy of settlement segmentation: resolving claims in state court where possible, using federal preemption as a cudgel to dismiss federal claims, and leaving objectors without a federal forum to challenge the global resolution.
The Eighth Circuit's dismissal confirms that this strategy works. For mass tort practitioners, the lesson is stark: the choice of forum is no longer just about procedural advantages or jury pools—it's about the very existence of appellate review. A state-court class settlement, once approved by a state trial judge, faces only state appellate review, which in Missouri (and many other jurisdictions) tends to be more deferential to trial court findings on settlement fairness than the increasingly skeptical federal bench.
The Objectors' Dilemma
The practical consequences for objecting plaintiffs are severe. In the federal MDL context, objectors to class settlements have increasingly found traction by arguing that settlements release claims without adequate compensation or fail to satisfy Rule 23(a)(4)'s adequacy requirement. The Eighth Circuit's decision removes that lever. Objectors who held federal claims—particularly those who might have opted out of the state-court class or challenged the settlement's scope—now find themselves locked out of federal court entirely.
This creates a perverse incentive structure. Defendants can effectively purchase peace at a discount by negotiating with state-court counsel who may have weaker incentives to maximize individual recovery (given the aggregate nature of state-court class practice) while facing reduced risk of federal appellate reversal. The $7.25 billion figure, while eye-popping, may actually represent a favorable per-claimant value for Bayer when compared to the potential exposure in the federal MDL, where bellwether trials had produced mixed results and where Judge Chhabria had expressed skepticism about broad releases.
What Comes Next
Expect this decision to accelerate the migration of mass tort settlements from federal MDLs to state-court class actions, particularly in jurisdictions with plaintiff-friendly certification standards and deferential appellate review. We are witnessing the federalization of mass torts in reverse: after decades of aggregation in federal courts under the MDL statute, defendants are now using jurisdictional boundaries to fragment oversight and limit appellate scrutiny.
For defense counsel, the playbook is clear: identify a receptive state forum, negotiate with local counsel to file a statewide or multistate class action, and structure the settlement to avoid federal question or diversity jurisdiction that would trigger removal. For plaintiffs' counsel, the warning is equally clear: if you file in federal court, you may find your claims resolved in a state-court settlement you cannot challenge, with releases that extinguish your clients' rights without federal appellate review.
The Eighth Circuit has not merely dismissed an appeal; it has endorsed a structural shift in how mass torts are resolved. Whether this represents efficient dispute resolution or a due process failure depends on one's view of the federal courts' role in policing class action fairness. But for now, the message to litigants is unmistakable: in the post-Roundup era, jurisdiction is destiny.
Tags
Published by AnrakLegal AI